Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of diacerein in preparing antiviral drugs and treating viral infections

A technology of diacerein and drugs, which is applied in the field of new uses of diacerein, and can solve problems such as no anti-virus reports of diacerein

Active Publication Date: 2022-03-25
CHINA INSPECTION SCI PHARM BEIJING GRP CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] However, there are no reports about diacerein antiviral, especially for some current major viruses such as hand, foot and mouth disease, HIV, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of diacerein in preparing antiviral drugs and treating viral infections
  • Use of diacerein in preparing antiviral drugs and treating viral infections
  • Use of diacerein in preparing antiviral drugs and treating viral infections

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0103] Exemplary Experimental Example 1. Cellular Pharmacodynamic Detection of the Inhibitory Effect of Diacerein on Human Enteroviruses

[0104]

[0105] 1. Cell culture, amplification and purification of EV-A71 virus

[0106] RD cells were cultured in DMEM medium containing 10% FBS. When the number of cells is sufficient, they are divided into 10 cm culture dishes with a density of 70%.

[0107] Put it in a 37-degree carbon dioxide incubator for cultivation. After 24 hours, dilute the virus with DMEM and discard the culture medium, add 4ml of virus diluent to each dish, and inoculate EV-A71 virus according to MOI=1. After adsorption at 37°C for 1 hour, the supernatant was discarded, and 10 ml of 5% FBS medium was added. Incubate at 37 degrees for 48 hours, and observe whether the cells have reached 50% detachment. The supernatant was collected and centrifuged at 2000 rpm for 10 minutes. Take the supernatant.

[0108] Prepare 5×PEG8000 NaCl solution. Preparation Wei...

experiment example 2

[0133] Exemplary Experiment 2. Cell-level Pharmacodynamic Detection of Diacerein's Inhibitory Effect on Hepatitis B Virus

[0134]

[0135] 1. Elisa assay was used to detect hepatitis B virus S antigen in the supernatant of the hepatitis B HepG2-2215 cell model.

[0136] The supernatant of HepG2-2215 cells treated with diacerein was aspirated, and the DMSO group was used as the control. According to the instructions of the detection kit, the pre-experiment tests the different dilution ratios of the cell supernatant, in order to meet the different dilution ratios within the range of the instrument.

[0137] The specific detection method is as follows:

[0138] Add the diluted cell supernatant to the enzyme-labeled wells, 100 microliters per well.

[0139] Incubate at 37 degrees for 1 hour to allow the S antigen to bind to the antibody (the antibody on the microplate in the kit).

[0140] Wash three times with wash solution, pat dry each time. Add 50 microliters of chromo...

experiment example 3

[0157] The result is as figure 2 As shown in C, diacerein does not cause significant cytotoxicity at concentrations below 25 μM. exemplary experiment Example 3. Cell-level pharmacodynamic detection of the inhibitory effect of diacerein on human immunodeficiency virus (HIV-1)

[0158]

[0159] 1. Packaging of HIV-1 pseudovirus

[0160] 293T cells were cultured in 10% FBS DMEM medium. A large number of plasmids of pNL4-3 Luc-R-E and VSVG were extracted, and the concentration and purity of the plasmids were measured by Nanodrop. The cells in better state were digested and divided into 10cm culture dishes. After culturing for 24 hours, discard the medium, rinse twice with DMEM, and add 5 ml of DMEM. Mix pNL4-3 Luc-R-E and VSVG medium 1:1 by mole ratio (the total mass is 6 micrograms), and add 60 microliters of PEI transfection reagent. Transfect 293T cells. After incubating at 37 degrees for 2 hours, add 4 ml of DMEM. The incubation was continued for 46 hours. Aspir...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The "Use of Diacerein in the Preparation of Antiviral Drugs and Treatment of Viral Infections" of the present invention belongs to the new application of Diacerein. Experiments have proved that Diacerein can effectively inhibit hepadnaviruses, retroviruses, intestinal Viruses, Orthomyxoviruses, Filoviruses, Reoviruses, Arenaviruses, Hepatitis Eviruses, Astroviruses, Orbiviruses, Coronaviruses, Parvoviruses, Adenoviruses, Polyomaviruses, Herpesviruses, Poxviruses , human papillomavirus, paramyxovirus, flavivirus, herpesvirus, alphavirus, rhabdovirus.

Description

technical field [0001] The invention relates to a new use of diacerein, in particular to the use of diacerein in preparing antiviral drugs and treating viral infections. Background technique [0002] Viruses have their own characteristics in transmission and infection routes, characteristics and mechanisms, and the mechanism of action of antiviral drugs is also divided into various types, such as directly inhibiting or killing viruses, interfering with virus adsorption, preventing viruses from penetrating into cells, inhibiting virus biosynthesis, Inhibit virus release or enhance host anti-virus ability, etc. Some viruses, such as hepadnaviruses, retroviruses, enteroviruses, and orthomyxoviruses, etc., face many difficulties in the treatment of viral diseases due to their special transmission routes, lack of effective preventive vaccines, virus mutations, and drug resistance. . [0003] For example, enteroviruses, which belong to the Picornaviridae family, usually break ou...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/222A61K31/192A61K31/122A61P31/20A61P31/22A61P31/14A61P31/16A61P31/18
CPCA61K31/222A61K31/192A61K31/122A61P31/20A61P31/22A61P31/14A61P31/16A61P31/18A61P31/12Y02A50/30
Inventor 朱水芳丛浩龙王晨光田志清姜帆
Owner CHINA INSPECTION SCI PHARM BEIJING GRP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com